Z-L-alanine methyl ester
Need Assistance?
  • US & Canada:
    +
  • UK: +

Z-L-alanine methyl ester

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

Category
CBZ-Amino Acids
Catalog number
BAT-003321
CAS number
28819-05-8
Molecular Formula
C12H15NO4
Molecular Weight
237.25
Z-L-alanine methyl ester
IUPAC Name
methyl (2S)-2-(phenylmethoxycarbonylamino)propanoate
Synonyms
Z-L-Ala-OMe
Appearance
White powder
Purity
≥ 98% (HPLC)
Density
1.01 g/cm3
Melting Point
45-49 °C
Boiling Point
101.5 °C
Storage
Store at 2-8°C
InChI
InChI=1S/C12H15NO4/c1-9(11(14)16-2)13-12(15)17-8-10-6-4-3-5-7-10/h3-7,9H,8H2,1-2H3,(H,13,15)/t9-/m0/s1
InChI Key
OMDVFTVXPVXANK-VIFPVBQESA-N
Canonical SMILES
CC(C(=O)OC)NC(=O)OCC1=CC=CC=C1

Z-L-alanine methyl ester, a versatile compound widely employed in chemical and biochemical, research boasts a multitude of applications. Here are the key applications of Z-L-alanine methyl ester described with high perplexity and burstiness:

Peptide Synthesis: A crucial reagent in peptide synthesis, Z-L-alanine methyl ester assumes the role of a protected amino acid building block aiding researchers in crafting peptides with meticulous sequences. By coupling it with other protected amino acids scientists intricately assemble peptides a fundamental process in developing therapeutic peptides and unraveling the intricacies of protein structure and function.

Enzyme Studies: Delving into enzymology Z-L-alanine methyl ester emerges as a valuable tool for exploring the specificity and mechanisms of protease enzymes. By integrating this ester into substrates, scientists delve into the catalytic properties and inhibition mechanisms of proteases shedding light on enzyme activity regulation and identifying potential drug targets for diseases entailing proteolytic enzymes.

Pharmaceutical Intermediates: Within pharmaceutical research and development, Z-L-alanine methyl ester plays a pivotal role as an intermediate in synthesizing diverse bioactive compounds. Serving as a precursor for amino acid derivatives and other intricate molecules this intermediate significantly contributes to drug discovery and the synthesis of therapeutic agents showcasing its versatility in advancing pharmaceutical science.

Chemical Synthesis: Moving beyond biological realms Z-L-alanine methyl ester finds utility in organic chemistry for synthesizing a diverse array of compounds Its incorporation into chiral catalysts and specialty chemicals capitalizes on its stereochemical properties to catalyze specific chemical reactions with exceptional precision and efficiency illustrating its potency in facilitating complex chemical synthesis processes.

1. Polypyridine ligands as potential metallo-β-lactamase inhibitors
Luana La Piana, Valentina Viaggi, Luigi Principe, Stefano Di Bella, Francesco Luzzaro, Maurizio Viale, Nadia Bertola, Graziella Vecchio J Inorg Biochem. 2021 Feb;215:111315. doi: 10.1016/j.jinorgbio.2020.111315. Epub 2020 Nov 21.
Bacteria have developed multiple resistance mechanisms against the most used antibiotics. In particular, zinc-dependent metallo-β-lactamase producing bacteria are a growing threat, and therapeutic options are limited. Zinc chelators have recently been investigated as metallo-β-lactamase inhibitors, as they are often able to restore carbapenem susceptibility. We synthesized polypyridyl ligands, N,N'-bis(2-pyridylmethyl)-ethylenediamine, N,N,N'-tris(2-pyridylmethyl)-ethylenediamine, N,N'-bis(2-pyridylmethyl)-ethylenediamine-N-acetic acid (N,N,N'-tris(2-pyridylmethyl)-ethylenediamine-N'-acetic acid, which can form zinc(II) complexes. We tested their ability to restore the antibiotic activity of meropenem against three clinical strains isolated from blood and metallo-β-lactamase producers (Klebsiella pneumoniae, Enterobacter cloacae, and Stenotrophomonas maltophilia). We functionalized N,N,N'-tris(2-pyridylmethyl)-ethylenediamine with D-alanyl-D-alanyl-D-alanine methyl ester with the aim to increase bacterial uptake. We observed synergistic activity of four polypyridyl ligands with meropenem against all tested isolates, while the combination N,N'-bis(2-pyridylmethyl)-ethylenediamine and meropenem was synergistic only against New Delhi and Verona integron-encoded metallo-β-lactamase-producing bacteria. All synergistic interactions restored the antimicrobial activity of meropenem, providing a significant decrease of minimal inhibitory concentration value (by 8- to 128-fold). We also studied toxicity of the ligands in two normal peripheral blood lymphocytes.
2. Catalytic asymmetric synthesis of α-methyl-p-boronophenylalanine
Shingo Harada, Ryota Kajihara, Risa Muramoto, Promsuk Jutabha, Naohiko Anzai, Tetsuhiro Nemoto Bioorg Med Chem Lett. 2018 Jun 1;28(10):1915-1918. doi: 10.1016/j.bmcl.2018.03.075. Epub 2018 Mar 28.
p-Boronophenylalanine (l-BPA) is applied in clinical settings as a boron carrier for boron neutron capture therapy (BNCT) to cure malignant melanomas. Structural modification or derivatization of l-BPA, however, to improve its uptake efficiency into tumor cells has scarcely been investigated. We successfully synthesized (S)-2-amino-3-(4-boronophenyl)-2-methylpropanoic acid in enantioenriched form as a novel candidate molecule for BNCT. Key steps to enhance the efficiency of this synthesis were enantioselective alkylation of N-protected alanine tert-butyl ester with a Maruoka catalyst and Miyaura borylation reaction to install the boron functionality.
3. Dietary salt with nitric oxide deficiency induces nocturnal polyuria in mice via hyperactivation of intrarenal angiotensin II-SPAK-NCC pathway
Y Sekii, H Kiuchi, K Takezawa, T Imanaka, S Kuribayashi, K Okada, Y Inagaki, N Ueda, S Fukuhara, R Imamura, H Negoro, N Nonomura Commun Biol. 2022 Feb 28;5(1):175. doi: 10.1038/s42003-022-03104-6.
Nocturnal polyuria is the most frequent cause of nocturia, a common disease associated with a compromised quality of life and increased mortality. Its pathogenesis is complex, and the detailed underlying mechanism remains unknown. Herein, we report that concomitant intake of a high-salt diet and reduced nitric oxide (NO) production achieved through Nω-Nitro-L-arginine methyl ester hydrochloride (L-NAME) administration in mice resulted in nocturnal polyuria recapitulating the clinical features in humans. High salt intake under reduced NO production overactivated the angiotensin II-SPAK (STE20/SPS1-related proline-alanine-rich protein kinase)-NCC (sodium chloride co-transporter) pathway in the kidney, resulting in the insufficient excretion of sodium during the day and its excessive excretion at night. Excessive Na excretion at night in turn leads to nocturnal polyuria due to osmotic diuresis. Our study identified a central role for the intrarenal angiotensin II-SPAK-NCC pathway in the pathophysiology of nocturnal polyuria, highlighting its potential as a promising therapeutic target.
Online Inquiry
Verification code
Inquiry Basket